
How Pharmaceutical Tariffs Will Affect US Health Care Costs
Tariffs on pharmaceuticals are under consideration following a Section 232 investigation into imports of medicines and active pharmaceutical ingredients (APIs).
Tariffs on pharmaceuticals are under consideration following a Section 232 investigation into imports of medicines and active pharmaceutical ingredients (APIs).
Today, MGA released a report in collaboration with the HDA measuring the economic impact of healthcare distributors in the United States.
This week, MGA released a new white paper by Alex Brill and Christy Robinson looking at the long-term effects of Medicare price negotiations on drug competition
As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.